SBC Medical Group Enters the Thai Market through Partnership with BLEZ
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced that it has entered into a Consulting Agreement with BLEZ ASIA Co., Ltd. (Headquarters: Bangkok, Thailand; CEO: Naoki Iida; “BLEZ”), which operates more than 20 pharmacies and clinics in Thailand and is widely trusted by both Japanese expatriates and local patients. The partnership is a key component of SBC’s broader Asia strategy and represents a significant step toward full-scale entry into the rapidly growing Thai aesthetic medicine market. Under the agreement, SBC will provide comprehensive management support to a new clinic focused primarily on dermatological treatments such as pigmentation and spot removal, which BLEZ is preparing to open in Bangkok. SBC will advise on clinical protocol development, aligned with SBC’s quality standards, and assist in selecting medical devices and treatment methods optimized for local skin characteristics and environmental conditions. The clinic is expected to commence operations by year-end in the Asok district of Bangkok.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251007584582/en/
SBC Medical Group Enters the Thai Market through Partnership with BLEZ
SBC operates a network of over 250 clinics worldwide, welcoming more than 6 million patient visits annually. By combining SBC’s proven expertise in delivering high-quality and safe aesthetic medical services developed in Japan with BLEZ’s trusted local presence, the two companies aim to establish a solid foothold among Japanese expatriates in Thailand. Following validation of service demand and operational performance, SBC and BLEZ intend to expand patient acquisition to the broader Thai market and pursue incremental growth opportunities across ASEAN.
According to industry research*, Thailand’s aesthetic medicine market was valued at approximately USD 372.24 million in 2024 and is projected to grow to USD 1.118 billion by 2033. With a forecasted compound annual growth rate (CAGR) of 13.51% from 2025 to 2033, Thailand has cemented its global position as a hub for medical tourism. Despite a population of around 60,000 Japanese expatriates, there are limited clinics offering “Japanese-quality” aesthetic treatments, and fragmented small-scale operators contribute to inconsistent service quality. This creates significant opportunities for large, reliable medical groups to meet growing demand with safe and consistent care.
*Source: Astute Analytica, USA and Asia Pacific Aesthetic Medicine Market – Industry Dynamics, Market Size, and Opportunity Forecast to 2033, 2025 Edition
BLEZ, a Japanese-owned company with over 10 years of medical experience in Bangkok, operates a diverse portfolio including BLEZ Pharmacy, BLEZ Kampo Pharmacy, internal medicine, dentistry, and even veterinary hospitals. Its annual patient base reaches approximately 1,200 for clinics and 100,000 for pharmacies. BLEZ also engages in the import and sale of pharmaceuticals, supplements, and medical devices, OEM manufacturing, FDA registrations in Thailand, telemedicine, and franchise businesses. This extensive network and strong brand presence will provide powerful support for SBC’s market entry.
In November 2024, SBC launched operations in Singapore through a partnership with Aesthetic Healthcare Holdings (AHH). The new collaboration with BLEZ represents the next step in SBC’s ASEAN expansion, accelerating its growth strategy across the region. Beginning with the Japanese expatriate community, SBC will steadily build its business foundation, aiming to deliver consistently high-level medical services and establish new value in the Thai aesthetic medicine market.
Naoki Iida, CEO of BLEZ ASIA Co., Ltd.
“The Thai aesthetic medicine market continues to grow rapidly, with increasing focus on quality and safety. Partnering with SBC, a leader in Japan with outstanding expertise and proven track record, is an invaluable opportunity for BLEZ. By combining our strengths, we aim to firmly establish Japanese-standard, high-quality medical services in Thailand and build a brand that will be trusted and loved by the community for years to come.”
Yoshiyuki Aikawa, CEO of SBC Medical Group Holdings, Inc.
“Japanese aesthetic medicine is globally competitive for its precision and high safety standards. SBC has been building its quality and reputation in Japan while preparing for global expansion. Partnering with a trusted local leader such as BLEZ in this fast-growing Thai market is a significant step forward in our Asia strategy. Together, we intend to create a model in which Japan’s advanced medical services can take root locally and deliver new value.”
About BLEZ ASIA Co., Ltd.
Company name: BLEZ ASIA Co., Ltd.
Established: January 10, 2012
Number of locations: 23
CEO: Naoki Iida
Headquarters: 415 Sukhumvit Road, Klongtoey Nua, Wattana, Bangkok 10110, Thailand
Website: https://blez-web.com
About SBC Medical Group Holdings Incorporated
SBC Medical Group Holdings Incorporated is a comprehensive medical group operating a wide range of franchise businesses across diverse medical fields, including advanced aesthetic medicine, dermatology, orthopedics, fertility treatment, dentistry, AGA (hair restoration), and ophthalmology. The Company manages a diverse portfolio of clinic brands and is actively expanding its global presence, particularly in the United States and Asia, through both direct operations and medical tourism initiatives. In September 2024, the Company was listed on Nasdaq, and in June 2025, it was selected for inclusion in the Russell 3000® Index, a broad benchmark of the U.S. equity market. Guided by its Group Purpose “Contributing to the well-being of people around the world through medical innovation,” SBC Medical Group Holdings Incorporated continues to provide safe, trusted, and high-quality medical services while further strengthening its international reputation for quality and trust in medical care.
For more information, visit https://sbc-holdings.com/
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company's beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company's control. These forward-looking statements reflect the Company's current views with respect to, among other things, the Company's product launch plans and strategies; growth in revenue and earnings; and business prospects. In some cases, forward-looking statements can be identified by the use of words such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," "targets" or "hopes" or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management's current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading "Risk Factors" and elsewhere in the Company's filings with the U.S. Securities and Exchange Commission (the "SEC"), which are accessible on the SEC's website at www.sec.gov.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251007584582/en/
Contacts
SBC Medical Group Holdings Incorporated
Hikaru Fukui / Head of IR Department
E-mail: ir@sbc-holdings.com
Akiko Wakiyama / Head of Public Relations
E-mail: pr@sbc.or.jp
ICR LLC (US Time)
Bill Zima / Managing Partner
Email: bill.zima@icrinc.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press Release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press Release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press Release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press Release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom